INFU
Price
$8.37
Change
+$0.41 (+5.15%)
Updated
Dec 20, 04:59 PM (EDT)
79 days until earnings call
XRAY
Price
$18.69
Change
+$0.22 (+1.19%)
Updated
Dec 20, 04:59 PM (EDT)
65 days until earnings call
Ad is loading...

INFU vs XRAY

Header iconINFU vs XRAY Comparison
Open Charts INFU vs XRAYBanner chart's image
InfuSystem Holdings
Price$8.37
Change+$0.41 (+5.15%)
Volume$400
CapitalizationN/A
DENTSPLY SIRONA
Price$18.69
Change+$0.22 (+1.19%)
Volume$303.78K
CapitalizationN/A
INFU vs XRAY Comparison Chart
Loading...
INFU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XRAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INFU vs. XRAY commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INFU is a Hold and XRAY is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (INFU: $8.31 vs. XRAY: $18.70)
Brand notoriety: INFU and XRAY are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: INFU: 168% vs. XRAY: 293%
Market capitalization -- INFU: $186.74M vs. XRAY: $6.69B
INFU [@Medical Specialties] is valued at $186.74M. XRAY’s [@Medical Specialties] market capitalization is $6.69B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INFU’s FA Score shows that 0 FA rating(s) are green whileXRAY’s FA Score has 1 green FA rating(s).

  • INFU’s FA Score: 0 green, 5 red.
  • XRAY’s FA Score: 1 green, 4 red.
According to our system of comparison, XRAY is a better buy in the long-term than INFU.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INFU’s TA Score shows that 5 TA indicator(s) are bullish while XRAY’s TA Score has 6 bullish TA indicator(s).

  • INFU’s TA Score: 5 bullish, 4 bearish.
  • XRAY’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, XRAY is a better buy in the short-term than INFU.

Price Growth

INFU (@Medical Specialties) experienced а -6.73% price change this week, while XRAY (@Medical Specialties) price change was -5.17% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.51%. For the same industry, the average monthly price growth was +1.92%, and the average quarterly price growth was +0.64%.

Reported Earning Dates

INFU is expected to report earnings on Mar 12, 2025.

XRAY is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Medical Specialties (-1.51% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XRAY($6.69B) has a higher market cap than INFU($187M). INFU has higher P/E ratio than XRAY: INFU (195.13) vs XRAY (19.23). INFU YTD gains are higher at: -21.157 vs. XRAY (-46.538). XRAY has higher annual earnings (EBITDA): 249M vs. INFU (16.2M). XRAY has more cash in the bank: 334M vs. INFU (161K). INFU has less debt than XRAY: INFU (36.3M) vs XRAY (2.3B). XRAY has higher revenues than INFU: XRAY (3.97B) vs INFU (123M).
INFUXRAYINFU / XRAY
Capitalization187M6.69B3%
EBITDA16.2M249M7%
Gain YTD-21.157-46.53845%
P/E Ratio195.1319.231,015%
Revenue123M3.97B3%
Total Cash161K334M0%
Total Debt36.3M2.3B2%
FUNDAMENTALS RATINGS
INFU vs XRAY: Fundamental Ratings
INFU
XRAY
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
97100
SMR RATING
1..100
8794
PRICE GROWTH RATING
1..100
4864
P/E GROWTH RATING
1..100
9290
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XRAY's Valuation (4) in the Medical Specialties industry is significantly better than the same rating for INFU (82). This means that XRAY’s stock grew significantly faster than INFU’s over the last 12 months.

INFU's Profit vs Risk Rating (97) in the Medical Specialties industry is in the same range as XRAY (100). This means that INFU’s stock grew similarly to XRAY’s over the last 12 months.

INFU's SMR Rating (87) in the Medical Specialties industry is in the same range as XRAY (94). This means that INFU’s stock grew similarly to XRAY’s over the last 12 months.

INFU's Price Growth Rating (48) in the Medical Specialties industry is in the same range as XRAY (64). This means that INFU’s stock grew similarly to XRAY’s over the last 12 months.

XRAY's P/E Growth Rating (90) in the Medical Specialties industry is in the same range as INFU (92). This means that XRAY’s stock grew similarly to INFU’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INFUXRAY
RSI
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 5 days ago
58%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
59%
Momentum
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
72%
MACD
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
55%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
71%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
72%
Advances
ODDS (%)
Bullish Trend 14 days ago
74%
Bullish Trend 12 days ago
58%
Declines
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
50%
Aroon
ODDS (%)
N/A
Bullish Trend 3 days ago
58%
View a ticker or compare two or three
Ad is loading...
INFU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XRAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MGRFX19.080.24
+1.27%
MassMutual Mid Cap Growth R5
FGIRX43.240.49
+1.15%
Fidelity Advisor Growth & Income A
ABVIX16.780.18
+1.08%
AB Large Cap Value I
RYWCX39.080.15
+0.39%
Rydex S&P SmallCap 600 Pure Growth C
EKGCX20.580.07
+0.34%
Allspring Special Global Small Cap C

INFU and

Correlation & Price change

A.I.dvisor indicates that over the last year, INFU has been loosely correlated with CRL. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if INFU jumps, then CRL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INFU
1D Price
Change %
INFU100%
+4.40%
CRL - INFU
41%
Loosely correlated
+1.99%
CTKB - INFU
37%
Loosely correlated
+2.10%
SMTI - INFU
36%
Loosely correlated
+6.62%
XRAY - INFU
35%
Loosely correlated
+1.25%
VMD - INFU
34%
Loosely correlated
-0.50%
More

XRAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with HBIO. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then HBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XRAY
1D Price
Change %
XRAY100%
+1.25%
HBIO - XRAY
45%
Loosely correlated
+0.48%
STE - XRAY
41%
Loosely correlated
+1.54%
NVST - XRAY
41%
Loosely correlated
+3.72%
KIDS - XRAY
41%
Loosely correlated
-0.93%
LH - XRAY
40%
Loosely correlated
+0.72%
More